John Mackey
John Mackey
Professor of Oncology, University of Alberta
Verified email at ualberta.ca - Homepage
Title
Cited by
Cited by
Year
Adjuvant trastuzumab in HER2-positive breast cancer
D Slamon, W Eiermann, N Robert, T Pienkowski, M Martin, M Press, ...
New England Journal of Medicine 365 (14), 1273-1283, 2011
21522011
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
SP Shah, A Roth, R Goya, A Oloumi, G Ha, Y Zhao, G Turashvili, J Ding, ...
Nature 486 (7403), 395-399, 2012
16552012
Adjuvant docetaxel for node-positive breast cancer
M Martin, T Pienkowski, J Mackey, M Pawlicki, JP Guastalla, C Weaver, ...
New England Journal of Medicine 352 (22), 2302-2313, 2005
12082005
Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis
ML McNeely, KL Campbell, BH Rowe, TP Klassen, JR Mackey, ...
Cmaj 175 (1), 34-41, 2006
11372006
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind …
LS Rosen, D Gordon, M Kaminski, A Howell, A Belch, J Mackey, ...
Cancer journal (Sudbury, Mass.) 7 (5), 377, 2001
10822001
Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial
KS Courneya, RJ Segal, JR Mackey, K Gelmon, RD Reid, ...
Journal of clinical oncology 25 (28), 4396-4404, 2007
10302007
Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or …
LS Rosen, D Gordon, M Kaminski, A Howell, A Belch, J Mackey, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2003
9732003
Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes
KS Courneya, JR Mackey, GJ Bell, LW Jones, CJ Field, AS Fairey
Journal of clinical oncology 21 (9), 1660-1668, 2003
8732003
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2–positive, hormone receptor …
B Kaufman, JR Mackey, MR Clemens, PP Bapsy, A Vaid, A Wardley, ...
Journal of Clinical Oncology 27 (33), 5529-5537, 2009
8712009
Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-> T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab …
DJ Slamon
Breast Cancer Res Treat 94, S5, 2005
850*2005
Gastric adenocarcinoma: review and considerations for future directions
BJ Dicken, DL Bigam, C Cass, JR Mackey, AA Joy, SM Hamilton
Annals of surgery 241 (1), 27, 2005
8242005
Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment
CMM Prado, VE Baracos, LJ McCargar, T Reiman, M Mourtzakis, ...
Clinical cancer research 15 (8), 2920-2926, 2009
7232009
Metabolic modulation of glioblastoma with dichloroacetate
ED Michelakis, G Sutendra, P Dromparis, L Webster, A Haromy, E Niven, ...
Science translational medicine 2 (31), 31ra34-31ra34, 2010
6822010
Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer
ED Michelakis, L Webster, JR Mackey
British journal of cancer 99 (7), 989-994, 2008
6422008
Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines
JR Mackey, RS Mani, M Selner, D Mowles, JD Young, JA Belt, ...
Cancer research 58 (19), 4349-4357, 1998
6131998
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial
J Hugh, J Hanson, MCU Cheang, TO Nielsen, CM Perou, C Dumontet, ...
Journal of clinical oncology 27 (8), 1168, 2009
6062009
Nucleoside analogues and nucleobases in cancer treatment
CM Galmarini, JR Mackey, C Dumontet
The lancet oncology 3 (7), 415-424, 2002
5732002
Nucleoside analogues: mechanisms of drug resistance and reversal strategies
CM Galmarini, JR Mackey, C Dumontet
Leukemia 15 (6), 875-890, 2001
5112001
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma
J Spratlin, R Sangha, D Glubrecht, L Dabbagh, JD Young, C Dumontet, ...
Clinical Cancer Research 10 (20), 6956-6961, 2004
4182004
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer
JJ Farrell, H Elsaleh, M Garcia, R Lai, A Ammar, WF Regine, R Abrams, ...
Gastroenterology 136 (1), 187-195, 2009
4092009
The system can't perform the operation now. Try again later.
Articles 1–20